Primary Site >> Colorectal Cancer
Gene >> TOMM34
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
Ref: Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. PMID: 16820880 |
Ref: NRF-1 is the major transcription factor regulating the expression of the human TOMM34 gene. PMID: 18364745 |
Ref: Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report. PMID: 22763829 Ref: [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer]. PMID: 23267878 |
Ref: Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. PMID: 23314271 Ref: [Treatment outcome of peptide vaccination for advanced colorectal cancer]. PMID: 24393856 |
Ref: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. PMID: 24612787 Ref: Proteogenomic characterization of human colon and rectal cancer. PMID: 25043054 Ref: [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer]. PMID: 25335716 |
Ref: Clinicopathological significance and prognostic value of Wilms' tumor gene expression in colorectal cancer. PMID: 26406403 |
Ref: Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer. PMID: 28266765 Ref: RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer. PMID: 28789449 |
Ref: IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides. PMID: 29498403 |